Valuation: Omeros Corporation

Market Cap 845M 742M 693M 636M 1.19B 80.9B 1.22B 8.21B 3.21B 40.03B 3.17B 3.1B 138B P/E 2026 *
-195x
P/E 2027 * 152x
Enterprise Value 845M 742M 693M 636M 1.19B 80.9B 1.22B 8.21B 3.21B 40.03B 3.17B 3.1B 138B EV / Sales 2026 *
12.5x
EV / Sales 2027 * 5.9x
Free-Float
96.44%
Yield 2026 *
-
Yield 2027 * -
1 day+3.46%
1 week+18.60%
Current month+22.71%
1 month+17.76%
3 months-19.85%
6 months-2.34%
Current year-32.05%
1 week 9.77
Extreme 9.77
11.89
1 month 9
Extreme 9
11.89
Current year 6.7
Extreme 6.7023
17.63
1 year 3.44
Extreme 3.435
17.65
3 years 0.92
Extreme 0.92
17.65
5 years 0.92
Extreme 0.92
17.65
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 1994-06-15
Director of Finance/CFO 62 2024-06-29
Chief Tech/Sci/R&D Officer 70 2019-10-31
Director TitleAgeSince
Chairman 67 1994-06-15
Director/Board Member 86 1994-12-31
Director/Board Member 72 1994-12-31
Date Insider Type Main position Quantity % Market Cap.
7/22/26 Free

Chief Financial Officer

105,000 0.1451%
7/22/26 Free

Chief Executive Officer

1,000,000 1.3817%
7/22/26 Free

General Counsel

105,000 0.1451%
Change 5-day change 1-year change 3-year change Capi.($)
+3.46%+18.60%+193.95%+167.66% 845M
+0.47%+2.27%+50.78%+70.84% 55.2B
+2.83%+0.48%+28.18%+82.59% 55.6B
+0.54%+1.22%-16.62%-13.47% 23.51B
-0.97%-3.30%-1.79%+383.00% 22.35B
-3.96%-3.31%+13.59%-13.97% 20.6B
-2.15%-2.30%+27.27%-31.03% 17.45B
-3.09%-7.00%+24.81%+541.96% 15.16B
-2.09%+0.64%+49.78%+178.74% 13.91B
-3.14%-8.47%+165.37%+292.18% 13.74B
Average -0.72%+0.72%+53.53%+165.85% 23.84B
Weighted average by Cap. -0.19%-0.45%+34.40%+129.12%

Financials

2026 *2027 *
Net sales 67.83M 59.61M 55.64M 51.06M 95.58M 6.5B 97.94M 660M 258M 3.22B 255M 249M 11.11B 143M 126M 117M 108M 202M 13.71B 207M 1.39B 544M 6.78B 537M 526M 23.45B
Net income -12.1M -10.63M -9.92M -9.11M -17.05M -1.16B -17.47M -118M -46.02M -574M -45.43M -44.44M -1.98B 1.25M 1.1M 1.03M 941K 1.76M 120M 1.8M 12.16M 4.75M 59.25M 4.69M 4.59M 205M
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
26-07-29 $11.67 +3.46% 1,686,053
26-07-28 $11.28 -0.53% 2,222,452
26-07-27 $11.34 +15.83% 3,360,609
26-07-24 $9.790 -4.77% 799,038
26-07-23 $10.28 +4.47% 1,544,963
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
11.67USD
Average target price
33.00USD
Spread / Average Target
+182.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock